U

University of California, San Francisco | UCSF Memory and Aging Center

Research site

(Unclaimed)

Location

675 Nelson Rising Lane, Suite 190, San Francisco, California, United States of America

Site insights

Top conditions

Top treatments

Davunetide

Verdiperstat

BMS-241027

AL002

Nimodipine

Lecanemab

LY3002813

FRM-0334

TPI-287

BIIB092

Parent organization

This site is a part of University of California, San Francisco

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 17 total trials

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease (INVOKE-2)

A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disea...

Active, not recruiting

Alzheimer Disease

Drug: Placebo

Drug: AL002

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting

Alzheimer Disease

Drug: Donanemab

Drug: Placebo

A Study of Lu AF82422 in Participants With Multiple System Atrophy (AMULET)

To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.

Active, not recruiting

Multiple System Atrophy

Drug: Placebo

Drug: Lu AF82422

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (Clarity AD)

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting

Early Alzheimer's Disease

Drug: Placebo

Drug: Lecanemab